

US011455754B2

(12) United States Patent

Chui et al.

(54) SYSTEM AND METHOD FOR SYNTHESIZING LOW-DIMENSIONAL IMAGE DATA FROM HIGH-DIMENSIONAL IMAGE DATA USING AN OBJECT GRID ENHANCEMENT

- (71) Applicant: HOLOGIC, INC., Marlborough, MA (US)
- Inventors: Haili Chui, Fremont, CA (US);
 Xiaomin Liu, Sunnyvale, CA (US);
 Xiangwei Zhang, Fremont, CA (US)
- (73) Assignee: Hologic, Inc., Marlborough, MA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 16/497,766
- (22) PCT Filed: Mar. 28, 2018
- (86) PCT No.: PCT/US2018/024912
 § 371 (c)(1),
 (2) Date: Sep. 25, 2019
- (87) PCT Pub. No.: WO2018/183549PCT Pub. Date: Oct. 4, 2018

(65) **Prior Publication Data**

US 2021/0118199 A1 Apr. 22, 2021

Related U.S. Application Data

- (60) Provisional application No. 62/479,008, filed on Mar. 30, 2017.
- (51) Int. Cl.

G06T 11/00	(2006.01)
G06N 20/00	(2019.01)
	(Continued)

(10) Patent No.: US 11,455,754 B2

(45) **Date of Patent:** Sep. 27, 2022

- - (Continued)
- (58) Field of Classification Search CPC ... G06T 11/005; G06T 7/0012; G06T 15/205; G06T 2207/10072; G06T 2207/10116; (Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,502,878 A	3/1970	Stewart
3,863,073 A	1/1975	Wagner
	(Cont	tinued)

FOREIGN PATENT DOCUMENTS

AU	2014339982 A1 *	5/2016	 A61B 6/481
CN	1846622	10/2006	
	(Cont	inued)	

OTHER PUBLICATIONS

M. Ertas, A. Akan, I. Yildirim, A. Dinler and M. Kamasak, "2D versus 3D total variation minimization in digital breast tomosynthesis," 2015 IEEE International Conference on Imaging Systems and Techniques (IST), Macau, 2015, pp. 1-4, doi: 10.1109/IST.2015. 7294553. (Year: 2015).*

(Continued)

Primary Examiner — Vu Le Assistant Examiner — Courtney Joan Nelson (74) Attorney, Agent, or Firm — Merchant & Gould P.C.

(57) **ABSTRACT**

A method for processing breast tissue image data includes processing image data of a patient's breast tissue to generate a high-dimensional grid depicting one or more high-dimensional objects in the patient's breast tissue; determining a probability or confidence of each of the one or more highdimensional objects depicted in the high-dimensional grid;

(Continued)



and modifying one or more aspects of at least one of the one or more high-dimensional objects based at least in part on its respective determined probability or confidence to thereby generate a lower-dimensional format version of the one or more high-dimensional objects. The method may further include displaying the lower-dimensional format version of the one or more high-dimensional objects in a synthesized image of the patient's breast tissue.

23 Claims, 9 Drawing Sheets

(51) Int. Cl.

A61B 6/00	(2006.01)
G06T 7/00	(2017.01)
G06T 15/20	(2011.01)

- (52) U.S. Cl. CPC .. *G06T 15/205* (2013.01); *G06T 2207/10072* (2013.01); *G06T 2207/10116* (2013.01); *G06T 2207/30068* (2013.01)

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3.971.950 A	7/1976	Evans et al.
4.160.906 A	7/1979	Daniels
4.310.766 A	1/1982	Finkenzeller et al.
4.496.557 A	1/1985	Malen et al.
4.559.641 A	12/1985	Caugant et al.
4.706.269 A	11/1987	Reina et al.
4.744.099 A	5/1988	Huettenrauch
4.773.086 A	9/1988	Fuiita
4.773.087 A	9/1988	Plewes
4.819.258 A	4/1989	Kleinman et al.
4,821,727 A	4/1989	Levene et al.
4,907,156 A	6/1990	Doi et al.
4,969,174 A	11/1990	Schied
4,989,227 A	1/1991	Tirelli et al.
5,018,176 A	5/1991	Romeas et al.
RE33,634 E	7/1991	Yanaki
5,029,193 A	7/1991	Saffer
5,051,904 A	9/1991	Griffith
5,078,142 A	1/1992	Siczek et al.
5,099,846 A	3/1992	Hardy
5,129,911 A	7/1992	Siczek et al.
5,133,020 A	7/1992	Giger et al.
5,163,075 A	11/1992	Lubinsky
5,164,976 A	11/1992	Scheid et al.
5,199,056 A	3/1993	Darrah
5,219,351 A	6/1993	Teubner
5,240,011 A	8/1993	Assa
5,279,309 A	1/1994	Taylor et al.
5,280,427 A	1/1994	Magnusson
5,289,520 A	2/1994	Pellegrino et al.
5,343,390 A	8/1994	Doi et al.
5,359,637 A	10/1994	Webbe
5,365,562 A	11/1994	Toker
5,386,447 A	1/1995	Siczek
5,415,169 A	5/1995	Siczek et al.
5,426,685 A	6/1995	Pellegrino et al.
5,452,367 A	9/1995	Bick
5,491,627 A	2/1996	Zhang et al.
5,499,097 A	3/1996	Ortyn et al.
5,506,877 A	4/1996	Niklason et al.
5,526,394 A	6/1996	Siczek
5,539,797 A	7/1996	Heidsieck et al.
5,553,111 A	9/1996	Moore

5 500 500 4	1/1007	D1
3,392,302 A	1/1997	ROOKS
5,594,769 A	1/199/	Pellegrino et al.
5,596,200 A	1/1997	Sharma
5.598.454 A	1/1997	Franetzki
5 609 152 A	3/1007	Pellegrino et al
5,607,152 A	5/1007	Andrew et al
5,027,809 A	5/1997	Andrew et al.
5,642,433 A	6/1997	Lee et al.
5.642.441 A	6/1997	Rilev et al.
5 647 025 A	7/1997	Frost et al
5 657 362 A	8/1007	Giger et al
5,057,502 A	0/1997	Giger et al.
5,668,889 A	9/1997	Hara
5,671,288 A	9/1997	Wilhelm et al.
5.712.890 A	1/1998	Spivev
5 719 952 A	2/1998	Rooks
5,715,552 A	4/1009	$C_{1}^{2} = 1$ $t = 1$
3,733,204 A	4/1998	Siczek et al.
5,763,871 A	6/1998	Ortyn et al.
5,769,086 A	6/1998	Ritchart et al.
5.773.832 A	6/1998	Saved et al.
5 803 912 A	0/1008	Siczek et al
5,005,912 A	10/1000	
5,818,898 A	10/1998	Isukamoto et al.
5,828,722 A	10/1998	Ploetz
5.835.079 A	11/1998	Shieh
5 841 124 A	11/1998	Ortvn et al
5 872 828 4	2/1000	Nikleson et el
5,872,828 A	2/1999	Nikiasoli et al.
5,875,258 A	2/1999	Ortyn et al.
5,878,104 A	3/1999	Ploetz
5,878,746 A	3/1999	Lemelson et al.
5 896 437 A	4/1999	Ploetz
5,070,437 A	9/1000	Tionetz
5,941,852 A	8/1999	Tumey
5,954,650 A	9/1999	Saito
5,986,662 A	11/1999	Argiro
6.005.907 A	12/1999	Ploetz
6 022 325 A	2/2000	Siczek et al
6.067.070 A	5/2000	SICZER EL al.
0,007,079 A	5/2000	Shien
6,075,879 A	6/2000	Roehrig et al.
6,091,841 A	7/2000	Rogers
6.101.236 A	8/2000	Wang et al.
6 102 866 A	8/2000	Nields et al
6,102,800 A	10/2000	
0,137,527 A	10/2000	Abdel-Malek
6,141,398 A	10/2000	He
6,149,301 A	11/2000	Kautzer et al.
6 175 117 B1	1/2001	Komardin
6 106 715 D1	2/2001	Nombu
(115 002 D1	3/2001	Nambu Davalara at al
6,215,892 BI	4/2001	Douglass et al.
6,216,540 B1	4/2001	Nelson
6,219,059 B1	4/2001	Argiro
6.256.370 B1	4/2001	Yavus
6 222 472 D1	5/2001	Shopord
(233,475 DI	6/2001	Z
0,243,441 BI	6/2001	Zur
6,245,028 B1	6/2001	Furst et al.
6,272,207 B1	8/2001	Tang
6.289.235 B1	9/2001	Webber et al.
6 202 530 B1	9/2001	Vavue
6 202 282 D1	0/2001	Lamalaan
0,295,202 DI	9/2001	
6,327,336 BI	12/2001	Gingold et al.
6,327,377 Bl	12/2001	Rutenberg et al.
6,341,156 B1	1/2002	Baetz
6.375.352 B1	4/2002	Hewes
6 389 104 B1	5/2002	Bani-Hashemi et al
6 411 926 D1	6/2002	Dati-Hasherin et al
0,411,830 BI	6/2002	Pater
6,415,015 B2	7/2002	Nicolas
6,424,332 B1	7/2002	Powell
6.442.288 B1	8/2002	Haerer
6 459 925 B1	10/2002	Nields et al
6 462 101 D2	10/2002	Duerte
0,403,181 BZ	10/2002	Duarte
0,408,226 Bl	10/2002	McIntyre, IV
6,480,565 B1	11/2002	Ning
6,501,819 B2	12/2002	Unger et al.
6.556.655 BI	4/2003	Chichereau
6 574 204 D1	6/2002	Heich
0,574,504 BI	0/2003	1151011
6,597,762 B1	7/2003	Ferrant
6,611,575 B1	8/2003	Alvassin et al.
6 620 111 B2	9/2003	Stephens et al
6 6 76 940 32	0/2003	Initar+ 1
0,020,849 B2	9/2003	nuitema et al.
6,633,674 B1	10/2003	Barnes
6.638.235 B2	10/2003	Miller et al.
6 647 002 P2	11/2002	Fberhard
0,047,092 DZ	11/2003	C 11
6,650,928 B1	11/2003	Gailly
6,683,934 B1	1/2004	Zhao

(56) **References** Cited

U.S. PATENT DOCUMENTS

C 7 4 4 9 49	Da	C/2004	Cto at a m	
0,744,848	DZ D2	6/2004	Stanton	
6,748,044	B2 D2	6/2004	Sabol et al.	
6,751,285	B2	6/2004	Eberhard	
6,758,824	BI	7/2004	Miller et al.	
6,813,334	B2	11/2004	Koppe	
6,882,700	B2	4/2005	Wang	
6,885,724	B2	4/2005	Li	
6,901,156	B2	5/2005	Giger et al.	
6,912,319	B1	5/2005	Barnes	
6.940.943	B2	9/2005	Claus	
6.978.040	B2	12/2005	Berestov	
6 987 331	B2	1/2006	Koenne	
6 000 554	B2	2/2006	Mertelmeier	
7 022 075	B2	4/2006	Grupwald et al	
7,022,075	D2 D2	4/2006	Diana at al	
7,023,723	D2 D1	4/2000	Dione et al.	
7,030,801	BI	4/2006	Westerman	
7,110,490	B2	9/2006	Eberhard	
7,110,502	B2	9/2006	Isuji	
7,117,098	BI	10/2006	Dunlay et al.	
7,123,684	B2	10/2006	Jing et al.	
7,127,091	B2	10/2006	OpDeBeek	
7,142,633	B2	11/2006	Eberhard	
7.218.766	B2 *	5/2007	Eberhard	A61B 6/463
· · ·				382/131
7.245.694	B2	7/2007	Jing et al.	0.020.000
7,289,825	B2	10/2007	Fors et al.	
7 298 881	B2	11/2007	Giger et al	
7 315 607	B2 B2	1/2008	Domenuer	
7,313,007	D2 D1	1/2008	Defreites et el	
7,319,733	D2 D2	1/2008	Denenas et al.	
7,323,092	BZ D2	1/2008	Rowlands	
7,346,381	B2	3/2008	Okerlund et al.	
7,406,150	B2	7/2008	Minyard et al.	
7,430,272	B2	9/2008	Jing et al.	
7,443,949	B2	10/2008	Defreitas et al.	
7,466,795	B2	12/2008	Eberhard et al.	
7,577,282	B2	8/2009	Gkanatsios et al.	
7,606,801	B2	10/2009	Faitelson et al.	
7,616,801	B2	11/2009	Gkanatsios et al.	
7,630,533	B2	12/2009	Ruth et al.	
7.634.050	B2	12/2009	Muller et al.	
7.640.051	B2	12/2009	Krishnan	
7 697 660	B2	4/2010	Ning	
7 702 142	B2	4/2010	Ren et al	
7 705 830	B2	4/2010	Westerman et al	
7,760,024	B2 B2	7/2010	Puth at al	
7,700,924	D2 D1	8/2010	Zahnigan	
7,709,219	BZ D2	8/2010	Zanniser	
7,787,930	B2 D2	8/2010	Kressy	
7,809,175	B2	10/2010	Roenrig et al.	
7,828,733	B2	11/2010	Zhang et al.	
7,831,296	B2	11/2010	DeFreitas et al.	
7,869,563	B2	1/2011	DeFreitas	
7,974,924	B2	7/2011	Holla et al.	
7,991,106	B2	8/2011	Ren et al.	
8,044,972	B2	10/2011	Hall et al.	
8,051,386	B2	11/2011	Rosander et al.	
8,126,226	B2	2/2012	Bernard et al.	
8,155,421	B2	4/2012	Ren et al.	
8.165.365	B2	4/2012	Bernard et al.	
8.532.745	B2	9/2013	DeFreitas et al.	
8.571.289	B2	10/2013	Ruth et al.	
8 594 274	B2	11/2013	Hoernig et al	
8 677 282	B2	3/2014	Craqun et al	
8,077,282	D2 D2	4/2014	Dop of al	
0,/12,12/	D2 D1	4/2014	Refi et al.	
0,071,333 8 082 150	טע נק	2/2014	Derioguerry et al	
0,903,130	D2	3/2013	r eriaswamy et al.	
9,020,579	<u>Б</u> 2	4/2015	Smith	
9,075,903	B2	7/2015	Marshall	
9,084,579	B2	7/2015	Ken et al.	
9,119,599	B2	9/2015	Itai	
9,129,362	B2	9/2015	Jerebko	
9,289,183	B2	3/2016	Karssemeijer	
9,451,924	B2	9/2016	Bernard	
9,456,797	B2	10/2016	Ruth et al.	
9.478.028	B2	10/2016	Parthasarathy	
9.589.374	B1	3/2017	Gao	
~,~~,~,~,~	<i></i> .	5/201/	~~~·	

9,592,019	B2	3/2017	Sugiyama
9,805,507	B2 B2	10/2017	Chen Ruth et al
9,811,758	B2	11/2017	Ren et al.
9,901,309	B2	2/2018	DeFreitas et al.
10,008,184	B2	6/2018	Kreeger et al.
10,010,302	B2 D2	10/2018	Ruth et al.
10,092,538	B2 B2	10/2018	Gkanatsios
10,242,490	B2	3/2019	Karssemeijer
10,335,094	B2	7/2019	DeFreitas
10,357,211	B2	7/2019	Smith
10,410,417	B2 B2	9/2019	Chen et al. Ruth et al
10,444,960	B2	10/2019	Marshall
10,456,213	B2	10/2019	DeFreitas
10,573,276	B2	2/2020	Kreeger et al.
10,575,807	B2 B2	3/2020	Granatsios DeFreitas
10,624,598	B2	4/2020	Chen
10,977,863	B2	4/2021	Chen
10,978,026	B2	4/2021	Kreeger
2001/0038681	AI A1	11/2001	Stanton et al.
2002/0012450	Al	1/2002	Tsuii
2002/0050986	Al	5/2002	Inoue
2002/0075997	Al	6/2002	Unger et al.
2002/0113681	Al	8/2002	Byram Maria at al
2002/0122333	A1 A1	12/2002	Barrette et al.
2002/0193676	Al	12/2002	Bodicker
2003/0007598	Al	1/2003	Wang
2003/0018272	Al	1/2003	Treado et al.
2003/0026386	A1 A1	3/2003	Tang Matusis
2003/0073895	Al	4/2003	Nields et al.
2003/0095624	A1	5/2003	Eberhard et al.
2003/0097055	Al	5/2003	Yanof
2003/0128893	A1 A1	7/2003	Castorina Burdette et al
2003/0159115	Al	9/2003	Karellas
2003/0194050	A1	10/2003	Eberhard
2003/0194121	Al	10/2003	Eberhard et al.
2003/0195433	AI A1	11/2003	Doan
2003/0212327	Al	11/2003	Wang
2003/0215120	Al	11/2003	Uppaluri
2004/0008809	Al	1/2004	Webber
2004/0008900	AI Al	1/2004	Avinash
2004/0036680	Al	2/2004	Davis
2004/0047518	A1	3/2004	Tiana
2004/0052328	Al	3/2004	Saboi
2004/0066884	AI Al	4/2004	Claus
2004/0066904	Al	4/2004	Eberhard et al.
2004/0070582	A1	4/2004	Smith et al.
2004/0077938	Al	4/2004	Mark et al.
2004/0081273	AI A1	4/2004 5/2004	Ning Brady
2004/0101095	Al	5/2004	Jing et al.
2004/0109028	A1	6/2004	Stern et al.
2004/0109529	Al	6/2004	Eberhard et al.
2004/0127789	A1 A1	7/2004	Ogawa Grupwald
2004/0171933	Al	9/2004	Stoller et al.
2004/0171986	A1	9/2004	Tremaglio, Jr. et al.
2004/0267157	A1	12/2004	Miller et al.
2005/0047636	A1 A1	3/2005 3/2005	Gines et al. Miller et al
2005/0049521	Al	3/2005	Defreitas et al.
2005/0078797	Al	4/2005	Danielsson et al.
2005/0084060	Al	4/2005	Seppi et al.
2005/0089205	A1	4/2005	Kapur
2005/0105679	Al	5/2005	Wu et al.
2005/010/689	A1 A1	5/2005	Sasano MacMahon
2005/0113681	Al	5/2005	DeFreitas et al.
2005/0112715	Δ1	5/2005	Schwindt et al

(56) **References** Cited

U.S. PATENT DOCUMENTS

2005/0124845	A1	6/2005	Thomadsen et al.
2005/0135555	A 1	6/2005	Claus
2005/0155555	AI	0/2005	Claus
2005/0135664	Al	6/2005	Kauthold
2005/0226375	A1	10/2005	Eberhard
2006/0000603	A 1	1/2006	Hanover et al
2000/00000000	A 1	1/2000	
2000/0018520	AI	1/2006	Avinash
2006/0025680	Al	2/2006	Jeune-Iomme
2006/0030784	A1	2/2006	Miller et al
2000/0030101	A 1	4/2006	Kaller et al
2000/00/4288	AI	4/2000	Keny et al.
2006/0098855	Al	5/2006	Gkanatsios et al.
2006/0129062	A1	6/2006	Nicoson et al.
2006/0132508	A 1	6/2006	Sadikali
2000/0132308	<u></u>	0/2000	
2006/014/099	AI	7/2006	Marshall et al.
2006/0155209	A1	7/2006	Miller et al.
2006/0197753	Δ1	9/2006	Hotelling
2000/01/7/33	A 1 %	0/2000	
2006/0210131	AI*	9/2006	wheeler, Jr G061 11/008
			382/128
2006/0228012	A 1	10/2006	Masuzawa
2000/0220012	A 1	10/2006	II
2000/0238540	AI	10/2006	Handley
2006/0257009	Al	11/2006	Wang
2006/0269040	A1	11/2006	Mertelmeier
2006/0201618	A 1	12/2006	Eborbord at al
2000/0291018	AI	12/2000	Ebernard et al.
2007/0019846	AI	1/2007	Bullitt et al.
2007/0030949	A1	2/2007	Jing et al.
2007/0036265	Δ1	2/2007	Ting et al
2007/0030203	AI 4 1	2/2007	Dig et al.
2007/0046649	AI	3/2007	Reiner
2007/0052700	A1	3/2007	Wheeler et al.
2007/0076844	A1	4/2007	Defreitas et al.
2007/0114424	A 1	5/2007	Danielsson et al
2007/0114424	AI	5/2007	Dameisson et al.
2007/0118400	Al	5/2007	Morita et al.
2007/0156451	A1	7/2007	Gering
2007/0223651	Δ1	9/2007	Wagenaar et al
2007/0225051	A 1	0/2007	Wallen alt at al
2007/0225600	AI	9/2007	weibrecht et al.
2007/0236490	Al	10/2007	Casteele
2007/0242800	A1	10/2007	Jing et al.
2007/0263765	A 1	11/2007	Wu
2007/0203703	AI	11/2007	Wu di
2007/0274585	AI	11/2007	Zhang et al.
2008/0019581	A1	1/2008	Gkanatsios et al.
2008/0043005	A 1	2/2008	Hassanpourgol
2000/0045903	A1	2/2008	
2008/0045855	AI	2/2008	Defreitas et al.
2008/0101537	A1	5/2008	Sendai
2008/0114614	A1	5/2008	Mahesh et al
2008/0125643	A 1	5/2008	Huisman
2008/0123043	AL	5/2008	Tuisman
2008/01309/9	AI	6/2008	Ren
2008/0139896	A1	6/2008	Baumgart
2008/0152086	Δ1	6/2008	Hall
2000/01/2000	A 1	7/2008	Christia at al
2008/0103130	AI	7/2008	Christie et al.
2008/0187095	Al	8/2008	Boone et al.
2008/0198966	A1	8/2008	Hiarn
2008/0221479	Δ1	9/2008	Ritchie
2000/0221475	A 1	0/2008	Chile alle a
2008/0229230	AI	9/2008	Shibaike
2008/0240533	A1	10/2008	Piron et al.
2008/0297482	A1	12/2008	Weice
2009/0003510			** 0135
	Δ1	1/2000	DeFreitas
2000/0005669	Al	1/2009	DeFreitas West et al
2009/0005668	A1 A1	1/2009 1/2009	DeFreitas West et al.
2009/0005668 2009/0010384	A1 A1 A1	1/2009 1/2009 1/2009	DeFreitas West et al. Jing et al.
2009/0005668 2009/0010384 2009/0034684	A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009	DeFreitas West et al. Jing et al. Bernard
2009/0005668 2009/0010384 2009/0034684 2009/0037821	A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009 2/2009	West et al. Jing et al. Bernard O.Neal et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821	A1 A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009 2/2009	DeFreitas West et al. Jing et al. Bernard O'Neal et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0079705	A1 A1 A1 A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009	DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0079705 2009/0080594	A1 A1 A1 A1 A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009	Versa DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0079705 2009/0080594 2009/0080607	A1 A1 A1 A1 A1 A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009	DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0079705 2009/0080594 2009/0080602	A1 A1 A1 A1 A1 A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009	Verso DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0079705 2009/0080594 2009/0080602 2009/0080604	A1 A1 A1 A1 A1 A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009	Versa DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/00379705 2009/0080602 2009/0080602 2009/0080604 2009/0080752	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009	Verss DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0079705 2009/0080594 2009/0080602 2009/0080604 2009/0080752 2009/0080755	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009	West et al. DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080602 2009/0080604 2009/0080755 2009/008765	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009	Verss DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080602 2009/0080602 2009/0080602 2009/0080604 2009/0080765 2009/0080765 2009/008765	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009	Verss DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Duth
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0079705 2009/0080594 2009/0080602 2009/0080602 2009/0080752 2009/0080765 2009/0087067 2009/0123052	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009	Versa DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Ruth
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080602 2009/0080604 2009/0080765 2009/0080765 2009/0087667 2009/0123052 2009/0123052	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009	Verss DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Ruth Daw et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0079705 2009/0080594 2009/0080602 2009/0080602 2009/0080765 2009/008765 2009/008767 2009/0123052 2009/0123659	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009	West et al. Jing et al. Bernard O'Neal et al. Bizelove et al. Brooks et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Ruth Daw et al. Defreitas et al
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080602 2009/0080602 2009/0080602 2009/0080605 2009/008765 2009/008765 2009/0087067 2009/0123052 2009/0123052 2009/0129644 2009/013592	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009 5/2009	West et al. DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Brooks et al. Bernard et al. Khorasani Ruth Daw et al. Defreitas et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080602 2009/0080604 2009/0080765 2009/0080765 2009/0087667 2009/0123052 2009/0123052 2009/0123052 2009/0123644	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009 5/2009	Verss DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Ruth Daw et al. Defreitas et al.
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080602 2009/0080602 2009/0080604 2009/0080752 2009/0080765 2009/0087067 2009/0123052 2009/0123052 2009/0123644 2009/0138280 2009/0138280	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009 5/2009 6/2009	West et al. DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Ruth Daw et al. Defreitas et al. Morita et al. Nields
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080602 2009/0080602 2009/0080604 2009/0080765 2009/0087067 2009/0123052 2009/0123052 2009/0123052 2009/0123052 2009/0123052 2009/0123644 2009/0135997 2009/0138280 2009/01437702	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009 5/2009 5/2009 5/2009 5/2009	Verso DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Ruth Daw et al. Defreitas et al. Morita et al. Nields Nurmi
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080594 2009/0080602 2009/0080604 2009/0080765 2009/0080765 2009/0123052 2009/0123052 2009/0123597 2009/0123597 2009/0123597 2009/0123597 2009/0123244	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009 5/2009 5/2009 5/2009 7/2009	Weiss DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Ruth Daw et al. Defreitas et al. Morita et al. Nields Nurmi
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080602 2009/0080602 2009/0080602 2009/0080752 2009/008765 2009/0087067 2009/0187067 2009/0123052 2009/0123052 2009/0138280 2009/0138280 2009/0143674 2009/0147702	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009 5/2009 5/2009 5/2009 7/2009 7/2009	Weiss DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Brooks et al. Ruth Bernard et al. Khorasani Ruth Daw et al. Defreitas et al. Morita et al. Nields Nurmi Ning
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080602 2009/0080602 2009/0080602 2009/0080752 2009/0087067 2009/0123052 2009/0123052 2009/0123052 2009/0123644 2009/0135997 2009/0135997 2009/0135997 2009/013674 2009/0143674 2009/0167702 2009/0171244 2009/0171244	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009 5/2009 5/2009 5/2009 7/2009 9/2009	Verss DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Ruth Daw et al. Defreitas et al. Nields Nurmi Ning Arakita
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0080594 2009/0080602 2009/0080602 2009/0080602 2009/0080752 2009/008765 2009/008765 2009/008765 2009/018205 2009/0135297 2009/0138280 2009/0138280 2009/013674 2009/0138280 2009/01285958	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009 5/2009 5/2009 5/2009 7/2009 7/2009 7/2009	Verso DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Brooks et al. Shores et al. Ruth Bernard et al. Khorasani Ruth Daw et al. Defreitas et al. Morita et al. Nields Nurmi Ning Arakita Ban
2009/0005668 2009/0010384 2009/0034684 2009/0037821 2009/0079705 2009/0080602 2009/0080602 2009/0080602 2009/008765 2009/008765 2009/0087067 2009/0123052 2009/0123052 2009/0123052 2009/0138280 2009/013674 2009/013674 2009/013674 2009/01384280 2009/0143674 2009/01384280 2009/0143674 2009/01384280 2009/0125885	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	1/2009 1/2009 1/2009 2/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 3/2009 5/2009 5/2009 5/2009 5/2009 5/2009 5/2009 7/2009 7/2009 9/2009 10/2009	Verss DeFreitas West et al. Jing et al. Bernard O'Neal et al. Sizelove et al. Brooks et al. Brooks et al. Brooks et al. Shores et al. Ruth Dernard et al. Khorasani Ruth Daw et al. Defreitas et al. Morita et al. Nields Nurmi Ning Arakita Ban Ren et al.

2009/0278812 A1	11/2009	Yasutake
2009/0296882 A1	12/2009	Gkanatsios et al
2000/0204147 11	12/2000	ling of al
2009/0304147 A1	2/2010	Mg et al.
2010/0034348 AI	2/2010	iu Dia
2010/0049046 AI	2/2010	Peiffer
2010/0054400 Al	. 3/2010	Ren et al.
2010/0079405 A1	4/2010	Bernstein
2010/0086188 A1	4/2010	Ruth et al
2010/0088346 11	4/2010	Urness et al
2010/00080340 A1	4/2010	Stor Logic at al
2010/0098214 AI	4/2010	Star-Lack et al.
2010/01058/9 AI	. 4/2010	Katayose et al.
2010/0121178 A1	. 5/2010	Krishnan
2010/0131294 A1	5/2010	Venon
2010/0131482 A1	5/2010	Linthicum et al.
2010/0135558 41	6/2010	Ruth et al
2010/0152570 11	6/2010	Navah
2010/0152570 AI	. 6/2010	Navad
2010/0166267 AI	//2010	Zhang
2010/0195882 A1	8/2010	Ren et al.
2010/0208037 A1	8/2010	Sendai
2010/0231522 A1	9/2010	Li
2010/0246000 A1	9/2010	Blum
2010/0240505 A1	10/2010	Equitannesse et al
2010/0259501 AI	10/2010	
2010/0259645 AI	10/2010	Kaplan
2010/0260316 Al	. 10/2010	Stein et al.
2010/0280375 A1	11/2010	Zhang
2010/0293500 A1	11/2010	Cragun
2011/0018817 A1	1/2011	Krvze
2011/0010017 /11	1/2011	Rigze
2011/0019891 AI	. 1/2011	ruong
2011/0054944 AI	3/2011	Sandberg et al.
2011/0069808 A1	. 3/2011	Defreitas et al.
2011/0069906 A1	3/2011	Park
2011/0087132 A1	4/2011	DeFreitas et al.
2011/0105879 A1	5/2011	Masumoto
2011/0109650 A1	5/2011	Kreeger
2011/0110576 A1	* 5/2011	Kreeger G16H 50/20
2011/01100/0 111		382/132
2011/0150447 11	6/2011	1:
2011/01/0447 AI	. 0/2011	
2011/0103939 AI	. 7/2011	lam et al.
2011/01/8389 AI	. 7/2011	Kumar et al.
2011/0182402 A1	. 7/2011	Partain
2011/0234630 A1	9/2011	Batman et al.
2011/0237927 A1	9/2011	Brooks et al.
2011/0242092 A1	10/2011	Kashiwagi
2011/02/12/09/2 111	12/2011	Georgiev et al
2011/0510120 A1	1/2012	Jang
2012/0014504 A1	* 1/2012	Karssomoijor G06T 7/0012
2012/0014578 AI	1/2012	Karssenleijer 0001 //0012
2012/00/0051 41	2/2012	382/131
2012/0069951 AI	. 3/2012	loba
2012/0131488 AI	5/2012	Karlsson et al.
2012/0133600 A1	. 5/2012	Marshall
2012/0133601 A1	5/2012	Marshall
2012/0134464 A1	5/2012	Hoernig et al.
2012/01/8151 A1	6/2012	Hamada
2012/0140131 A1	7/2012	Ianahla
2012/0189092 AI	. //2012	Jerebko
2012/0194425 AI	8/2012	Buelow
2012/02388/0 AI	9/2012	Smith et al.
2012/0293511 A1	. 11/2012	Mertelmeier
2013/0022165 A1	1/2013	Jang
2013/0044861 A1	2/2013	Muller
2013/0059758 A1	* 3/2013	Haick B82Y 15/00
		977/773
2013/0108138 41	5/2013	Nakayama
2013/0121560 41	5/2013	Vaday
2013/0121309 A1	5/2013	Tadav N 1
2013/0121618 AI	5/2013	Yadav
2013/0202168 AI	* 8/2013	Jerebko G061 11/006
		202/121
2012/0250102 11		382/131
2015/0259195 AI	10/2013	Packard 382/131
2013/02/39193 A1 2014/0033126 A1	10/2013 1/2014	Packard Kreeger
2013/0239193 A1 2014/0033126 A1 2014/0035811 A1	10/2013 1/2014 2/2014	382/131 Packard Kreeger Guehring
2013/0239195 A1 2014/0033126 A1 2014/0035811 A1 2014/0064444 A1	10/2013 1/2014 2/2014 3/2014	382/131 Kreeger Guehring Oh
2013/0239193 A1 2014/0033126 A1 2014/0035811 A1 2014/0064444 A1 2014/0073913 A1	10/2013 1/2014 2/2014 3/2014 3/2014	382/131 Packard Kreeger Guehring Oh DeFreitas et al
2013/0239193 A1 2014/0033126 A1 2014/0035811 A1 2014/0064444 A1 2014/0073913 A1 2014/0219534 A1	10/2013 1/2014 2/2014 3/2014 3/2014 8/2014	382/131 Fackard Kreeger Guehring Oh DeFreitas et al. Wiemker et al
2013/0239195 A1 2014/0033126 A1 2014/0035811 A1 2014/0064444 A1 2014/0073913 A1 2014/0219534 A1	10/2013 1/2014 2/2014 3/2014 3/2014 8/2014	382/131 Fackard Kreeger Guchring Oh DeFreitas et al. Wiemker et al.
2014/0033126 A1 2014/0035811 A1 2014/0064444 A1 2014/0073913 A1 2014/0219534 A1 2014/0219534 A1	10/2013 1/2014 2/2014 3/2014 3/2014 8/2014 8/2014	382/131 Fackard Kreeger Guehring Oh DeFreitas et al. Wiemker et al. Wels et al.
2013/0239193 A1 2014/0033126 A1 2014/0054811 A1 2014/0064444 A1 2014/0073913 A1 2014/0219534 A1 2014/0219548 A1 2014/0227702 A1	10/2013 1/2014 2/2014 3/2014 3/2014 8/2014 8/2014 11/2014	382/131 Kreeger Guehring Oh DeFreitas et al. Wiemker et al. Wels et al. Kreeger et al. Cl
2013/0239193 A1 2014/0033126 A1 2014/0035811 A1 2014/0073913 A1 2014/0219534 A1 2014/0219548 A1 2014/0219548 A1 2014/0327702 A1	10/2013 1/2014 2/2014 3/2014 3/2014 8/2014 8/2014 8/2014 11/2014	382/131 Salarian Salarian Sal
2013/0239193 A1 2014/0035811 A1 2014/0035811 A1 2014/0073913 A1 2014/0219534 A1 2014/0219548 A1 2014/0327702 A1 2014/0327702 A1 2014/0327712 A1	10/2013 1/2014 2/2014 3/2014 3/2014 8/2014 8/2014 11/2014 11/2014 2/2015	382/131 Sachard Kreeger Guchring Oh DeFreitas et al. Wiemker et al. Wels et al. Kreeger et al. Gluncic Chen et al.
2013/0239193 A1 2014/0035811 A1 2014/0035811 A1 2014/0064444 A1 2014/0073913 A1 2014/0219534 A1 2014/0219548 A1 2014/0328517 A1 2014/0328517 A1 2015/0052471 A1 2015/0052471 A1	10/2013 1/2014 2/2014 3/2014 3/2014 8/2014 8/2014 11/2014 11/2014 11/2014 2/2015 4/2015	382/131 Sachard Kreeger Guehring Oh DeFreitas et al. Wiemker et al. Wels et al. Kreeger et al. Gluncic Chen et al. Smith et al.
2013/0239193 A1 2014/0035811 A1 2014/0035811 A1 2014/0073913 A1 2014/0219534 A1 2014/0219534 A1 2014/0219548 A1 2014/0328517 A1 2015/0052471 A1 2015/0051582 A1 2015/038148 A1	10/2013 1/2014 2/2014 3/2014 3/2014 8/2014 11/2014 11/2014 11/2014 2/2015 8/2015	382/131 Sachard Kreeger Guehring Oh DeFreitas et al. Wiemker et al. Wels et al. Kreeger et al. Gluncic Chen et al. Smith et al. Georgescu
2013/0239193 A1 2014/0033811 A1 2014/0035811 A1 2014/0035811 A1 2014/0073913 A1 2014/0219534 A1 2014/0219548 A1 2014/03227702 A1 2014/03227702 A1 2015/0052471 A1 2015/0061582 A1 2015/0238148 A1 2015/0238148 A1	10/2013 1/2014 2/2014 3/2014 8/2014 8/2014 11/2014 11/2014 2/2015 4/2015 8/2015	382/131 Sachard Kreeger Guehring Oh DeFreitas et al. Wiemker et al. Wels et al. Kreeger et al. Gluncic Chen et al. Smith et al. Georgescu Marshall

JP

JP

2012-501750

2012011255

1/2012

1/2012

(56) **References Cited**

U.S. PATENT DOCUMENTS

2015/0309712	A1	10/2015	Marshall
2015/0317538	A1	11/2015	Ren et al.
2015/0331995	A1	11/2015	Zhao
2016/0000399	A1	1/2016	Halmann et al.
2016/0022364	A1	1/2016	DeFreitas et al.
2016/0051215	A1	2/2016	Chen
2016/0078645	A1	3/2016	Abdurahman et al.
2016/0140749	A1	5/2016	Erhard
2016/0228034	A1	8/2016	Gluncic
2016/0235380	A1	8/2016	Smith
2016/0367210	A1	12/2016	Gkanatsios
2017/0071562	A1	3/2017	Suzuki
2017/0262737	A1	9/2017	Rabinovich
2018/0047211	A1	2/2018	Chen et al.
2018/0137385	A1	5/2018	Ren
2018/0144244	A1	5/2018	Masoud
2018/0256118	A1	9/2018	DeFreitas
2019/0015173	A1	1/2019	DeFreitas
2019/0043456	A1	2/2019	Kreeger
2019/0290221	A1	9/2019	Smith
2020/0046303	A1	2/2020	DeFreitas
2020/0093562	A1	3/2020	DeFreitas
2020/0184262	A1	6/2020	Chui
2020/0205928	A1	7/2020	DeFreitas
2020/0253573	A1	8/2020	Gkanatsios
2020/0345320	A1	11/2020	Chen
2020/0390404	A1	12/2020	DeFreitas
2021/0000553	A1	1/2021	St. Pierre
2021/0100518	A1	4/2021	Chui
2021/0100626	A1	4/2021	St. Pierre
2021/0113167	A1	4/2021	Chui
2022/0005277	A1	1/2022	Chen
2022/0013089	A1	1/2022	Kreeger
2022/0192615	A1	6/2022	Chui

FOREIGN PATENT DOCUMENTS

CN	202161228	3/2012
CN	102420678	5/2012
CN	102429078	12/2012
DE	102010000205	8/2011
DE	102011087127	5/2011
	775467	5/2013
ED	082001	3/1997
	1428472	6/2000
	1428473	6/2004
	2230083	8/2010
	2213000	3/2010
	2301432	3/2011
	2491803	8/2012
	1980348	1/2013
	2030789	1/2015
EP	2823404	1/2015
EP	2823703	1/2015
EP	3060132	4/2019
JP m	H09-198490	0/1007
JP ID	10 22522	9/1997
JP	10-33523	2/1998
JP	H10-33523	2/1998
JP	2000-200340	10/2000
JP	2002-282248	10/2002
JP	2003-189179	7/2003
JP	2003-199737	10/2003
JP	2003-531516	10/2003
JP	2006-519634	8/2006
JP	2006-312026	11/2006
JP	2007-130487	5/2007
JP	2007-330334	12/2007
JP	2007-536968	12/2007
JP	2008-068032	3/2008
JP	2009-034503	2/2009
JP	2009-522005	6/2009
JL JL	2009-526618	7/2009
JL JL	2009-207545	9/2009
1b 1b	2010-137004	6/2010
JP	2011-110175 A	6/2011

JP	2012-061196		3/2012		
JP	2013-244211		12/2013		
JP	2014-507250		3/2014		
JP	2014-534042		12/2014		
JP	2015-506794		3/2015		
JP	2015-144632	Α	8/2015		
JP	2016-198197		12/2015		
KR	10-2015-0010515		1/2015		
KR	10-2017-0062839		6/2017		
WO	90/05485		5/1990		
WO	93/17620		9/1993		
WO	94/06352		3/1994		
WO	1997/00649		1/1997		
WO	1998/16903		4/1998		
WO	00/51484		9/2000		
WO	2003/020114		3/2003		
WO	2005051197		6/2005		
WO	2005/110230		11/2005		
WO	2005110230		11/2005		
WO	2005/112767		12/2005		
WÕ	2005112767		12/2005		
WÕ	2006/055830		5/2006		
wõ	2006/058160		6/2006		
wõ	2007/095330		8/2007		
wõ	08/014670		2/2008		
wõ	2008047270		4/2008		
wõ	2008/054436		5/2008		
wõ	2009/026587		2/2009		
wõ	2010/028208		3/2010		
wõ	2010059920		5/2010		
wõ	2011008239		1/2011		
wõ	2011/043838		4/2011		
wõ	2011/01/2020		6/2011		
wo	2011003550		6/2011		
wo	20110733004		7/2011		
wo	2011091500		1/2012		
wo	2012/068373		5/2012		
wo	2012/000373		5/2012		
wo	2012003033		8/2012		
WO	2012/112027		0/2012		
wo	2012/122333		1/2012		
wo	2013/035026		3/2013		
WO	2013/078476		5/2013		
wo	WO_2013123001	A1 *	8/2013		A61B 6/466
wo	2017/170554	л	0/2013	•••••	A01D 0/400
WO	WO2014/207080		12/2014		
wo	WO_2014/207080	A1 *	$\frac{12}{2014}$		G06T 15/08
wo	2015/061582	л	4/2014		0001 15/08
wo	2015/061582		5/2015		
wo	2015/000050		9/2015		
wo	2015/150910		6/2015		
wo	2010/103094		11/2016		
wo	2010/104/40		10/2019		
wo	2010/102340		10/2010		
WO	WO2018/182540		10/2010		
wo	w02018/183549		10/2018		
wo	2018/236565		12/2018		

OTHER PUBLICATIONS

B. E. Caroline and N. Vaijayanthi, "Computer aided detection of masses in digital breast tomosynthesis: A review," 2012 International Conference on Emerging Trends in Science, Engineering and Technology (INCOSET), Tiruchirappalli, 2012, pp. 186-191, doi: 10.1109/INCOSET.2012.6513903 (Year: 2012).*

International Search Report and Written Opinion dated Jun. 8, 2018 for PCT application No. PCT/US2018/024912, applicant Hologic, Inc., 10 pages.

Non-Final Office Action for U.S. Appl. No. 16/497,767 dated Feb. 19, 2021.

U.S. Appl. No. 16/497,767, Office Action dated Jul. 16, 2021, 26 pages.

PCT International Preliminary Report on Patentability in International Application PCT/US2018/024912, dated Oct. 10, 2019, 7 pages.

(56) **References Cited**

OTHER PUBLICATIONS

"Filtered Back Projection", (Nygren), published May 8, 2007, URL: http://web.archive.org/web/19991010131715/http://www.owlnet.rice.edu/~elec539/Projects97/cult/node2.html, 2 pgs.

Berg, WA et al., "Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer", JAMA 299:2151-2163, 2008.

Carton, AK, et al., "Dual-energy contrast-enhanced digital breast tomosynthesis—a feasibility study", BR J Radiol. Apr. 2010;83 (988):344-50.

Chen, SC, et al., "Initial clinical experience with contrast-enhanced digital breast tomosynthesis", Acad Radio. Feb. 2007 14(2):229-38. Diekmann, F., et al., "Digital mammography using iodine-based contrast media: initial clinical experience with dynamic contrast medium enhancement", Invest Radiol 2005; 40:397-404.

Dromain C., et al., "Contrast enhanced spectral mammography: a multi-reader study", RSNA 2010, 96th Scientific Assembly and Scientific Meeting.

Dromain, C., et al., "Contrast-enhanced digital mammography", Eur J Radiol. 2009; 69:34-42.

Freiherr, G., "Breast tomosynthesis trials show promise", Diagnostic Imaging—San Francisco 2005, V27; N4:42-48.

Giger et al. "Development of a smart workstation for use in mammography", in Proceedings of SPIE, vol. 1445 (1991), p. 101103; 4 pages.

Giger et al., "An Intelligent Workstation for Computer-aided Diagnosis", in RadioGraphics, May 1993, 13:3 pp. 647-656; 10 pages. Hologic, "Lorad StereoLoc II" Operator's Manual 9-500-0261, Rev. 005, 2004, 78 pgs.

Hologic, Inc., 510(k) Summary, prepared Nov. 28, 2010, for Affirm Breast Biopsy Guidance System Special 510(k) Premarket Notification, 5 pages.

Hologic, Inc., 510(k) Summary, prepared Aug. 14, 2012, for Affirm Breast Biopsy Guidance System Special 510(k) Premarket Notification, 5 pages.

ICRP Publication 60: 1990 Recommendations of the International Commission on Radiological Protection, 12 pages.

Jochelson, M., et al., "Bilateral Dual Energy contrast-enhanced digital mammography: Initial Experience", RSNA 2010, 96th Scientific Assembly and Scientific Meeting, 1 page.

Jong, RA, et al., Contrast-enhanced digital mammography: initial clinical experience. Radiology 2003; 228:842-850.

Kopans, et al. Will tomosynthesis replace conventional mammography? Plenary Session SFN08: RSNA 2005.

Lehman, CD, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295-1303.

Lewin, JM, et al., Dual-energy contrast-enhanced digital subtraction mammography: feasibility. Radiology 2003; 229:261-268.

Lindfors, KK, et al., Dedicated breast CT: initial clinical experience. Radiology 2008; 246(3): 725-733.

Niklason, L., et al., Digital tomosynthesis in breast imaging. Radiology. Nov. 1997; 205(2):399-406.

Poplack, SP, et al., Digital breast tomosynthesis: initial experience in 98 women with abnormal digital screening mammography. AJR Am J Roentgenology Sep. 2007 189(3):616-23.

Prionas, ND, et al., Contrast-enhanced dedicated breast CT: initial clinical experience. Radiology. Sep. 2010 256(3):714-723.

Rafferty, E et al., "Assessing Radiologist Performance Using Combined Full-Field Digital Mammography and Breast Tomosynthesis Versus Full-Field Digital Mammography Alone: Results"

presented at 2007 Radiological Society of North America meeting, Chicago IL.

Shrading, Simone et al., "Digital Breast Tomosynthesis-guided Vacuum-assisted Breast Biopsy: Initial Experiences and Comparison with Prone Stereotactic Vacuum-assisted Biopsy", the Department of Diagnostic and Interventional Radiology, Univ. of Aachen, Germany, published Nov. 12, 2014, 10 pgs.

Smith, A., "Full field breast tomosynthesis", Radiol Manage. Sep.-Oct. 2005; 27(5):25-31.

Weidner N, et al., "Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma", New England Journal of Medicine 1991; 324:1-8.

Weidner, N, "The importance of tumor angiogenesis: the evidence continues to grow", AM J Clin Pathol. Nov. 2004 122(5):696-703. "Supersonic to feature Aixplorer Ultimate at ECR", AuntiMinnie. com, 3 pages (Feb. 2018).

Bushberg, Jerrold et al., "The Essential Physics of Medical Imaging", 3rd ed., In: "The Essential Physics of Medical Imaging, Third Edition", Dec. 28, 2011, Lippincott & Wilkins, Philadelphia, PA, USA, XP05579051, pp. 270-272.

Dromain, Clarisse et al., "Dual-energy contrast-enhanced digital mammography: initial clinical results", European Radiology, Sep. 14, 2010, vol. 21, pp. 565-574.

Reynolds, April, "Stereotactic Breast Biopsy: A Review", Radiologic Technology, vol. 80, No. 5, Jun. 1, 2009, pp. 447M-464M, XP055790574.

Fischer Imaging Corp, Mammotest Plus manual on minimally invasive breast biopsy system, 2002, 8 pages. (Reference labeled D13 in 01 Opposition).

Fischer Imaging Corporation, Installation Manual, MammoTest Family of Breast Biopsy Systems, 86683G, 86684G, P-55957-IM, Issue 1, Revision 3, Jul. 2005, 98 pages. (Reference labeled D12 in 01 Opposition).

Fischer Imaging Corporation, Operator Manual, MammoTest Family of Breast Biopsy Systems, 86683G, 86684G, P-55956-OM, Issue 1, Revision 6, Sep. 2005, 258 pages. (Reference labeled D11 in 01 Opposition).

Koechli, Ossi R., "Available Sterotactic Systems for Breast Biopsy", Renzo Brun del Re (Ed.), Minimally Invasive Breast Biopsies, Recent Results in Cancer Research 173:105-113; Springer-Verlag, 2009. (Reference labeled D10 in 01 Opposition).

E. Shaw de Paredes et al., "Interventional Breast Procedure", published Sep./Oct. 1998 in Curr Probl Diagn Radiol, pp. 138-184. (D15 in oppo).

Burbank, Fred, "Stereotactic Breast Biopsy: Its History, Its Present, and Its Future", published in 1996 at the Southeastern Surgical Congress, 24 pages.

Georgian-Smith, Dianne, et al., "Stereotactic Biopsy of the Breast Using an Upright Unit, a Vacuum-Suction Needle, and a Lateral Arm-Support System", 2001, at the American Roentgen Ray Society meeting, 8 pages. (Reference labeled D10 in 0020 Opposition). Samani, A. et al., "Biomechanical 3-D Finite Element Modeling of the Human Breast Using MRI Data", 2001, IEEE Transactions on Medical Imaging, vol. 20, No. 4, pp. 271-279.

Yin, H.M., et al., "Image Parser: a tool for finite element generation from three-dimensional medical images", BioMedical Engineering Online. 3:31, pp. 1-9, Oct. 1, 2004.

Sakic et al., "Mammogram synthesis using a 3D simulation. I. breast tissue model and image acquisition simulation" Medical Physics. 29, pp. 2131-2139 (2002).

Wołajo, Felasfa, MD, "Now Playing: Radiology Images from Your Hospital PACS on your iPad," Mar. 17, 2010; web site: http://www. imedicalapps.com/2010/03/now-playing-radiology-images-from-your-hospital-pacs-on-your-ipad/, accessed on Nov. 3, 2011 (3 pages).

Pathmanathan et al., "Predicting tumour location by simulating large deformations of the breast using a 3D finite element model and nonlinear elasticity", Medical Image Computing and Computer-Assisted Intervention, pp. 217-224, vol. 3217 (2004).

Al Sallab et al., "Self Learning Machines Using Deep Networks", Soft Computing and Pattern Recognition (SoCPaR), 2011 Int'l. Conference of IEEE, Oct. 14, 2011, pp. 21-26.

Ghiassi, M. et al., "A Dynamic Architecture for Artificial Networks", Neurocomputing, vol. 63, Aug. 20, 2004, pp. 397-413.

Chan, Heang-Ping et al., "ROC Study of the effect of stereoscopic imaging on assessment of breast lesions," Medical Physics, vol. 32, No. 4, Apr. 2005, 1001-1009.

Lilja, Mikko, "Fast and accurate voxel projection technique in free-form cone-beam geometry with application to algebraic reconstruction," Applies Sciences on Biomedical and Communication Technologies, 2008, Isabel '08, first international symposium on, IEEE, Piscataway, NJ, Oct. 25, 2008.

(56) **References Cited**

OTHER PUBLICATIONS

Pediconi, "Color-coded automated signal intensity-curve for detection and characterization of breast lesions: Preliminary evaluation of new software for MR-based breast imaging," International Congress Series 1281 (2005) 1081-1086.

eFilm Mobile HD by Merge Healthcare, web site: http://itunes. apple.com/bw/app/efilm-mobile-hd/id405261243?mt=8, accessed on Nov. 3, 2011 (2 pages).

eFilm Solutions, eFilm Workstation (tm) 3.4, website: http://estore. merge.com/na/estore/content.aspx?productID=405, accessed on Nov. 3, 2011 (2 pages).

Van Schie, Guido, et al., "Mass detection in reconstructed digital breast tomosynthesis volumes with a computer-aided detection system trained on 2D mammograms", Med. Phys. 40(4), Apr. 2013, 41902-1-41902-11.

Van Schie, Guido, et al., "Generating Synthetic Mammograms from Reconstructed Tomosynthesis Volumes", IEEE Transactions on Medical Imaging, vol. 32, No. 12, Dec. 2013, 2322-2331. Diekmann, Felix et al., "Thick Slices from Tomosynthesis Data

Diekmann, Felix et al., "Thick Slices from Tomosynthesis Data Sets: Phantom Study for the Evaluation of Different Algorithms", Journal of Digital Imaging, Springer, vol. 22, No. 5, Oct. 23, 2007, pp. 519-526.

Conner, Peter, "Breast Response to Menopausal Hormone Therapy— Aspects on Proliferation, apoptosis and Mammographic Density", 2007 Annals of Medicine, 39:1, 28-41.

Glick, Stephen J., "Breast CT", Annual Rev. Biomed. Eng., 2007, 9:501-26.

Metheany, Kathrine G. et al., "Characterizing anatomical variability in breast CT images", Oct. 2008, Med. Phys. 35 (10); 4685-4694. Dromain, Clarisse, et al., "Evaluation of tumor angiogenesis of breast carcinoma using contrast-enhanced digital mammography", AJR: 187, Nov. 2006, 16 pages. Zhao, Bo, et al., "Imaging performance of an amorphous selenium digital mammography detector in a breast tomosynthesis system", May 2008, Med. Phys 35(5); 1978-1987.

Mahesh, Mahadevappa, "AAPM/RSNA Physics Tutorial for Residents—Digital Mammography: An Overview", Nov.-Dec. 2004, vol. 24, No. 6, 1747-1760.

Zhang, Yiheng et al., "A comparative study of limited-angle conebeam reconstruction methods for breast tomosythesis", Med Phys., Oct. 2006, 33(10): 3781-3795.

Sechopoulos, et al., "Glandular radiation dose in tomosynthesis of the breast using tungsten targets", Journal of Applied Clinical Medical Physics, vol. 8, No. 4, Fall 2008, 161-171.

Wen, Junhai et al., "A study on truncated cone-beam sampling strategies for 3D mammography", 2004, IEEE, 3200-3204.

Ijaz, Umer Zeeshan, et al., "Mammography phantom studies using 3D electrical impedance tomography with numerical forward solver", Frontiers in the Convergence of Bioscience and Information Technologies 2007, 379-383.

Kao, Tzu-Jen et al., "Regional admittivity spectra with tomosynthesis images for breast cancer detection", Proc. Of the 29th Annual Int'l. Conf. of the IEEE EMBS, Aug. 23-26, 2007, 4142-4145.

Varjonen, Mari, "Three-Dimensional Digital Breast Tomosynthesis in the Early Diagnosis and Detection of Breast Cancer", IWDM 2006, LNCS 4046, 152-159.

Taghibakhsh, f. et al., "High dynamic range 2-TFT amplified pixel sensor architecture for digital mammography tomosynthesis", IET Circuits Devices Syst., 2007, 1(10, pp. 87-92.

Chan, Heang-Ping et al., "Computer-aided detection system for breast masses on digital tomosynthesis mammograms: Preliminary Experience", Radiology, Dec. 2005, 1075-1080.

* cited by examiner



























SYSTEM AND METHOD FOR SYNTHESIZING LOW-DIMENSIONAL IMAGE DATA FROM HIGH-DIMENSIONAL IMAGE DATA USING AN OBJECT GRID ENHANCEMENT

RELATED APPLICATIONS DATA

The present application is a National Phase entry under 35 U.S.C § 371 of International Patent Application No. PCT/¹⁰ US2018/024912, having an international filing date of Mar. 28, 2018, which claims the benefit under 35 U.S.C. § 119 to U.S. Provisional Patent Application Ser. No. 62/479,008, filed Mar. 30, 2017, which is incorporated by reference in its entirety into the present application.¹⁵

FIELD

The presently disclosed inventions relate to systems and methods for processing and displaying breast tissue images, ²⁰ and in particular to representing high-dimensional (e.g., 3D) structures present in breast tissue image data with a highdimensional object grid, and then reducing the high-dimensional data to a low-dimensional (e.g., 2D) format version that can be incorporated within a synthesized image to be ²⁵ displayed to a medical professional.

BACKGROUND

Mammography has long been used to screen for breast 30 cancer and other abnormalities. Traditionally, mammograms have been formed on x-ray film. More recently, flat panel digital imagers have been introduced that acquire a mammogram in digital form, and thereby facilitate analysis and storage of the acquired image data, and to also provide other 35 benefits. Further, substantial attention and technological development have been dedicated to obtaining three-dimensional images of the breast using methods such as breast tomosynthesis. In contrast to the 2D images generated by legacy mammography systems, breast tomosynthesis sys- 40 tems construct a 3D image volume from a series of 2D projection images, each projection image obtained at a different angular displacement of an x-ray source relative to the image detector as the x-ray source is scanned over the detector. The constructed 3D image volume is typically 45 presented as a plurality of slices of image data, the slices being mathematically reconstructed on planes typically parallel to the imaging detector. The reconstructed tomosynthesis slices reduce or eliminate the problems caused by tissue overlap and structure noise present in single slice, 50 two-dimensional mammography imaging, by permitting a user (e.g., a radiologist or other medical professional) to scroll through the image slices to view only the structures in that slice.

Imaging systems such as tomosynthesis systems have 55 recently been developed for breast cancer screening and diagnosis. In particular, Hologic, Inc. (hologic.com) has developed a fused, multimode mammography/tomosynthesis system that acquires one or both types of mammogram and tomosynthesis images, either while the breast remains 60 immobilized or in different compressions of the breast. Other companies have introduced systems that include tomosynthesis imaging; e.g., which do not include the ability to also acquire a mammogram in the same compression. 65

Examples of systems and methods that leverage existing medical expertise in order to facilitate, optionally, the tran-

sition to tomosynthesis technology are described in U.S. Pat. No. 7,760,924, which is hereby incorporated by reference in its entirety. In particular, U.S. Pat. No. 7,760,924 describes a method of generating a synthesized 2D image, which may optionally be displayed along with tomosynthesis projection or reconstructed images, in order to assist in screening and diagnosis.

A 2D synthesized image is designed to provide a concise representation of the 3D reconstruction slices, including any clinically important and meaningful information, such as abnormal lesions and normal breast structures, while representing in relevant part a traditional 2D image. There are many different types of lesions and breast structures, which may be defined as different types of image objects having different characteristics. For any given image object visible in the 3D volume data, it is important to maintain and enhance the image characteristics (e.g., micro-calcifications, architectural distortions, etc.) as much as possible onto the 2D synthesized image. Further, when representing multiple identified objects on the 2D synthesized image, the synthesized image may appear crowded and visually confusing. Accordingly, there exists a need for more effectively processing, synthesizing and displaying breast image data.

SUMMARY

In one embodiment of the disclosed inventions, a method for processing breast tissue image data includes obtaining image data of a patient's breast tissue; processing the image data to generate a high-dimensional grid depicting one or more high-dimensional objects in the patient's breast tissue; determining a probability or confidence of each of the one or more high-dimensional objects depicted in the high-dimensional grid; and generating a lower-dimensional format version of the one or more high-dimensional objects for display in a synthesized image of the patient's breast tissue.

These and other aspects and embodiments of the disclosed inventions are described in more detail below, in conjunction with the accompanying figures.

BRIEF DESCRIPTION OF THE FIGURES

The drawings illustrate the design and utility of embodiments of the disclosed inventions, in which similar elements are referred to by common reference numerals. These drawings are not necessarily drawn to scale. In order to better appreciate how the above-recited and other advantages and objects are obtained, a more particular description of the embodiments will be rendered, which are illustrated in the accompanying drawings. These drawings depict only typical embodiments of the disclosed inventions and are not therefore to be considered limiting of its scope.

FIG. 1 is a block diagram illustrating the flow of data through an exemplary breast image acquisition and processing system in accordance with embodiments of the disclosed inventions;

FIG. **2** is a block diagram illustrating the flow of data through a 2D synthesizer employing a 3D object grid and various modules that reduce objects of the grid to a 2D format for display;

FIG. 3 illustrates a first synthesized image formed from the 3D object grid of FIG. 2 without manipulating overlapping objects, and a second synthesized image formed from the same 3D object grid, but with manipulation of overlapping objects;

FIG. **4A-4D** illustrate exemplary techniques for combining objects onto one or more 2D synthesized images;

FIG. **5** illustrates an exemplary flow diagram depicting combining objects from a 3D object grid onto a 2D synthesized image; and

FIG. 6 illustrates an exemplary flow diagram depicting generating one or more 2D synthesized images using a 3D 5 object grid.

DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS

All numeric values are herein assumed to be modified by the terms "about" or "approximately," whether or not explicitly indicated, wherein the terms "about" and "approximately" generally refer to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In some instances, the terms "about" and "approximately" may include numbers that are rounded to the nearest significant figure. The recitation of numerical ranges by endpoints includes all numbers within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).

As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the content clearly dictates otherwise. As used in this 25 specification and the appended claims, the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise. In describing the depicted embodiments of the disclosed inventions illustrated in the accompanying figures, specific terminology is 30 employed for the sake of clarity and ease of description. However, the disclosure of this patent specification is not intended to be limited to the specific terminology so selected, and it is to be understood that each specific element includes all technical equivalents that operate in a similar 35 manner. It is to be further understood that the various elements and/or features of different illustrative embodiments may be combined with each other and/or substituted for each other wherever possible within the scope of this disclosure and the appended claims.

Various embodiments of the disclosed inventions are described hereinafter with reference to the figures. It should be noted that the figures are not drawn to scale and that elements of similar structures or functions are represented by like reference numerals throughout the figures. It should 45 also be noted that the figures are only intended to facilitate the description of the embodiments. They are not intended as an exhaustive description of the invention or as a limitation on the scope of the disclosed inventions, which is defined only by the appended claims and their equivalents. In 50 addition, an illustrated embodiment of the disclosed inventions needs not have all the aspects or advantages shown. For example, an aspect or an advantage described in conjunction with a particular embodiment of the disclosed inventions is not necessarily limited to that embodiment and 55 can be practiced in any other embodiments even if not so illustrated.

For the following defined terms and abbreviations, these definitions shall be applied throughout this patent specification and the accompanying claims, unless a different 60 definition is given in the claims or elsewhere in this specification:

An "acquired image" refers to an image generated while visualizing a patient's tissue. Acquired images can be generated by radiation from a radiation source impacting on a 65 radiation detector disposed on opposite sides of a patient's tissue, as in a conventional mammogram.

A "reconstructed image" refers to an image generated from data derived from a plurality of acquired images. A reconstructed image simulates an acquired image not included in the plurality of acquired images.

A "synthesized image" refers to an artificial image generated from data derived from a plurality of acquired and/or reconstructed images. A synthesized image includes elements (e.g., objects and regions) from the acquired and/or reconstructed images, but does not necessarily correspond to an image that can be acquired during visualization. Synthesized images are constructed analysis tools.

An "Mp" image is a conventional mammogram or contrast enhanced mammogram, which are two-dimensional (2D) projection images of a breast, and encompasses both a digital image as acquired by a flat panel detector or another imaging device, and the image after conventional processing to prepare it for display (e.g., to a health professional), storage (e.g., in the PACS system of a hospital), and/or other use.

A "Tp" image is an image that is similarly two-dimensional (2D), but is acquired at a respective tomosynthesis angle between the breast and the origin of the imaging x-rays (typically the focal spot of an x-ray tube), and encompasses the image as acquired, as well as the image data after being processed for display, storage, and/or other use.

A "Tr" image is a type (or subset) of a reconstructed image that is reconstructed from tomosynthesis projection images Tp, for example, in the manner described in one or more of U.S. Pat. Nos. 7,577,282, 7,606,801, 7,760,924, and 8,571,289, the disclosures of which are fully incorporated by reference herein in their entirety, wherein a Tr image represents a slice of the breast as it would appear in a projection x-ray image of that slice at any desired angle, not only at an angle used for acquiring Tp or Mp images.

An "Ms" image is a type (or subset) of a synthesized image, in particular, a synthesized 2D projection image, which simulates mammography images, such as craniocau-40 dal (CC) or mediolateral oblique (MLO) images, and is constructed using tomosynthesis projection images Tp, tomosynthesis reconstructed images Tr, or a combination thereof. Ms images may be provided for display to a health professional or for storage in the PACS system of a hospital 45 or another institution. Examples of methods that may be used to generate Ms images are described in the aboveincorporated U.S. Pat. Nos. 7,760,924 and 8,571,289.

It should be appreciated that Tp, Tr, Ms and Mp image data encompasses information, in whatever form, that is sufficient to describe the respective image for display, further processing, or storage. The respective Mp, Ms. Tp and Tr images are typically provided in digital form prior to being displayed, with each image being defined by information that identifies the properties of each pixel in a two-dimensional array of pixels. The pixel values typically relate to respective measured, estimated, or computed responses to X-rays of corresponding volumes in the breast, i.e., voxels or columns of tissue. In a preferred embodiment, the geometry of the tomosynthesis images (Tr and Tp) and mammography images (Ms and Mp) are matched to a common coordinate system, as described in U.S. Pat. No. 7,702,142. Unless otherwise specified, such coordinate system matching is assumed to be implemented with respect to the embodiments described in the ensuing detailed description of this patent specification.

The terms "generating an image" and "transmitting an image" respectively refer to generating and transmitting

information that is sufficient to describe the image for display. The generated and transmitted information is typically digital information.

In order to ensure that a synthesized 2D image displayed to an end-user (e.g., an Ms image) includes the most clinically relevant information, it is necessary to detect and identify three-dimensional (3D) objects, such as malignant breast mass, tumors, etc., within the breast tissue. In accordance with the inventions disclosed and described herein, this information may be used to create a high-dimensional grid, e.g., a 3D grid, that helps create a more accurate and enhanced rendering of the most important features in the synthesized 2D image. The high-dimensional object grid may then be used to collapse the most clinically-significant information pertaining to the identified objects to a 2D format onto one or more synthesized 2D images. Various data reduction techniques may be applied to the identified 3D objects to ensure that the most clinically-significant objects are emphasized, and less significant objects are 20 omitted and/or de-emphasized. Additionally, or alternatively, data reduction techniques are applied to ensure that significant features of a 3D object are enhanced, while less significant features of the 3D object are de-emphasized, especially when two objects are competing for display and 25 prominence on the one or more 2D synthesized images. Thus, as disclosed and described herein, a 3D object grid is utilized, i.e., as a component of an algorithm, for reducing high-dimensional data (e.g., 3D tomosynthesis image data) to low-dimensional data (e.g. a 2D synthesized image).

FIG. 1 illustrates the flow of data in an exemplary image generation and display system 100, which incorporates each of synthesized image generation, object identification, and display technology. It should be understood that, while FIG. 1 illustrates a particular embodiment of a flow diagram with 35 certain processes taking place in a particular serial order or in parallel, the claims and various other embodiments described herein are not limited to the performance of the image processing steps in any particular order, unless so specified.

More particularly, the image generation and display system 100 includes an image acquisition system 101 that acquires tomosynthesis image data for generating Tp images of a patient's breasts, using the respective three-dimensional and/or tomosynthesis acquisition methods of any of the 45 currently available systems. If the acquisition system is a combined tomosynthesis/mammography system, Mp images may also be generated. Some dedicated tomosynthesis systems or combined tomosynthesis/mammography systems may be adapted to accept and store legacy mam- 50 mogram images, (indicated by a dashed line and legend "Mp_{legacy}" in FIG. 1) in a storage device 102, which is preferably a DICOM-compliant Picture Archiving and Communication System (PACS) storage device. Following acquisition, the tomosynthesis projection images Tp may 55 also be transmitted to the storage device 102 (as shown in FIG. 1). The storage device 102 may further store a library of known 3D objects that may be used to identify significant 3D image patterns to the end-user. In other embodiments, a separate dedicated storage device (not shown) may be used 60 to store the library of known 3D objects with which to identify 3D image patterns or objects.

The Tp images are transmitted from either the acquisition system 101, or from the storage device 102, or both, to a computer system configured as a reconstruction engine 103 65 that reconstructs the Tp images into reconstructed image "slices" Tr, representing breast slices of selected thickness

and at selected orientations, as disclosed in the aboveincorporated patents and applications.

Mode filters 107 are disposed between image acquisition and image display. The filters 107 may additionally include customized filters for each type of image (i.e., Tp, Mp, and Tr images) arranged to identify and highlight certain aspects of the respective image types. In this manner, each imaging mode can be tuned or configured in an optimal way for a specific purpose. For example, filters programmed for recognizing objects across various 2D image slices may be applied in order to detect image patterns that may belong to a particular high-dimensional object. The tuning or configuration may be automatic, based on the type of the image, or may be defined by manual input, for example through a user interface coupled to a display. In the illustrated embodiment of FIG. 1, the mode filters 107 are selected to highlight particular characteristics of the images that are best displayed in respective imaging modes, for example, geared towards identifying objects, highlighting masses or calcifications, identifying certain image patterns that may be constructed into a 3D object, or for creating 2D synthesized images (described below). Although FIG. 1 illustrates only one mode filter 107, it should be appreciated that any number of mode filters may be utilized in order to identify structures of interest in the breast tissue.

The imaging and display system 100 further includes a 2D image synthesizer 104 that operates substantially in parallel with the reconstruction engine 103 for generating 2D synthesized images using a combination of one or more Tp, Mp, and/or Tr images. The 2D image synthesizer 104 consumes a set of input images (e.g., Mp, Tr and/or Tp images), determines a set of most relevant features from each of the input images, and outputs one or more synthesized 2D images. The synthesized 2D image represents a consolidated synthesized image that condenses significant portions of various slices onto one image. This provides an end-user (e.g., medical personnel, radiologist, etc.) with the most clinically-relevant image data in an efficient manner, and reduces time spent on other images that may not have significant data.

One type of relevant image data to highlight in the synthesized 2D images would be relevant objects found across one or more Mp, Tr and/or Tp images. Rather than simply assessing image patterns of interest in each of the 2D image slices, it may be helpful to determine whether any of the 2D image patterns of interest belong to a larger highdimensional structure, and if so, to combine the identified 2D image patterns into a higher-dimensional structure. This approach has several advantages, but in particular, by identifying high-dimensional structures across various slices/ depths of the breast tissue, the end-user may be better informed as to the presence of a potentially significant structure that may not be easily visible in various 2D slices of the breast.

Further, instead of identifying similar image patterns in two 2D slices (that are perhaps adjacent to each other), and determining whether or not to highlight image data from one or both of the 2D slices, identifying both image patterns as belonging to the same high-dimensional structure may allow the system to make a more accurate assessment pertaining to the nature of the structure, and consequently provide significantly more valuable information to the end-user. Also, by identifying the high-dimensional structure, the structure can be more accurately depicted on the synthesized 2D image. Yet another advantage of identifying high-dimensional structures within the various captured 2D slices of the breast tissue relates to identifying a possible size/scope of the identified higher-dimensional structure. For example, once a structure has been identified, previously unremarkable image patterns that are somewhat proximate to the high-dimensional structure may now be identified as belonging to the same structure. This may provide the end-user 5 with an indication that the high-dimensional structure is increasing in size/scope.

To this end, the 2D image synthesizer 104 generates high-dimensional object grids 120 (e.g., 3D object grids) comprising one or more high-dimensional structures (e.g., 10 3D objects) present in the patient's breast tissue. Several techniques may be used to construct 3D object grids 120 that identify various objects in the breast tissue. It should be appreciated that this disclosure is not limited to 3D objects and/or structures, and may refer to even higher-dimensional 15 structures, but for simplicity, the remaining disclosure will refer to 3D objects populated in a 3D object grid 120.

In one or more embodiments, the 3D object grid 120 is in the form of a 3D (volumetric) coordinate space representing a patient's breast mass, and identifies a location, identity, 20 size, scope, and/or other characteristics of any objects or structures found in the breast mass. Examples of such objects or structures include calcifications, spiculated lesions, benign tumors, irregular masses, dense objects, etc.

In one or more embodiments, the end-user (e.g., a medical 25 professional such as a radiologist) can access and interact with the 3D object grid 120. In other embodiments, the 3D object grid 120 is solely used by the system processor for constructing synthesized 2D images, and the end-user may not be aware of, or have access to, the 3D object grid 120. 30

In accordance with the disclosed embodiments, the 2D image synthesizer 104 also includes a data reduction module 122 configured to reduce the high-dimensional data populated in the 3D object grid 120 to a lower-dimensional format suitable for representation in a 2D synthesized 35 image. The data reduction module 122 evaluates the various objects of the 3D object grid 120, and determines what objects (or what portions of objects) should be enhanced or emphasized in a final 2D synthesized image to be displayed to the end-user. For example, a clinically significant object 40 and a routine background breast tissue object may have regions of overlap, in which case the data reduction module 122 is preferably configured to de-emphasize portions of the background breast tissue in order to highlight the clinically significant object. Further details on various data reduction 45 techniques that may be employed by the data reduction module 122 are described below.

The synthesized 2D images may be viewed at a display system 105. The reconstruction engine 103 and 2D image synthesizer 104 are preferably connected to a display system 50 105 via a fast transmission link. The display system 105 may be part of a standard acquisition workstation (e.g., of acquisition system 101), or of a standard (multi-display) review station (not shown) that is physically remote from the acquisition system 101. In some embodiments, a display 55 connected via a communication network may be used, for example, a display of a personal computer or of a so-called tablet, smart phone or other hand-held device. In any event, the display 105 of the system is preferably able to display respective Ms, Mp, Tr, and/or Tp images concurrently, e.g., 60 in separate side-by-side monitors of a review workstation, although the invention may still be implemented with a single display monitor, by toggling between images.

Thus, the imaging and display system 100, which is described as for purposes of illustration and not limitation, 65 is capable of receiving and selectively displaying tomosynthesis projection images Tp, tomosynthesis reconstruction

8

images Tr, synthesized mammogram images Ms, and/or mammogram (including contrast mammogram) images Mp, or any one or sub combination of these image types. The system 100 employs software to convert (i.e., reconstruct) tomosynthesis images Tp into images Tr, software for synthesizing mammogram images Ms, software for decomposing 3D objects, software for creating feature maps and object maps. An object of interest or feature in a source image may be considered a 'most relevant' feature for inclusion in a 2D synthesized image based upon the application of the object maps along with one or more algorithms and/or heuristics, wherein the algorithms assign numerical values, weights or thresholds, to pixels or regions of the respective source images based upon identified/detected objects and features of interest within the respective region or between features. The objects and features of interest may include, for example, spiculated lesions, calcifications, and the like.

FIG. 2 illustrates the 2D image synthesizer 104 in further detail. As discussed above, various image slices 218 of a tomosynthesis data set (or "stack") 202 (e.g., filtered and/or unfiltered Mp, Tr and/or Tp images of a patient's breast tissue) are input into the 2D image synthesizer 104, and then processed to determine portions of the images to highlight in a synthesized 2D image that will be displayed on the display 105. The image slices 218 may be consecutively-captured cross-sections of a patient's breast tissue. Or, the image slices 218 may be cross-sectional images of the patient's breast tissue captured at known intervals. The tomosynthesis image stack 202 comprising the image slices 218 may be forwarded to the 2D image synthesizer 104, which evaluates each of the source images in order to (1) identify various types of objects (Tr) for possible inclusion in one or more 2D synthesized images, and/or (2) identify respective pixel regions in the images that contain the identified objects.

As shown in the illustrated embodiment, the tomosynthesis stack 202 comprises a plurality of images 218 taken at various depths/cross-sections of the patient's breast tissue. Some of the images 218 in the tomosynthesis stack 202 comprise 2D image patterns. Thus, the tomosynthesis stack 202 comprises a large number of input images containing various image patterns within the images of the stack.

For example, while the tomosynthesis stack 202 may comprise one hundred images 218 captured at various depths/cross sections of the patient's breast tissue, only a few of the images 218 may include any information of significance. Also, it should be noted that the tomosynthesis stack 202 contains 2D image patterns when viewed at differing z-dimension (depth) locations of the otherwise same x, y locations in the image slices 218, but it may be difficult to determine the 3D structures based only on the various individual images, each representing a finite crosssectional image of the breast tissue. However, the tomosynthesis stack **202** may be effectively utilized to create the 3D object grid 120. In any event, for purposes of this patent specification, it is assumed that the 3D object grid 120 is constructed by any means, including but not limited to being created from the tomosynthesis stack 202.

The 3D object grid 120 may be considered a 3D volumetric coordinate space representing a patient's breast mass. Rather than depicting 2D image patterns at various image slices, the 3D object grid 120 preferably depicts any identified 3D objects in the entire mass (or portion thereof) that represents the patient's breast tissue. The 3D object grid 120 provides fuller detail regarding various objects in the breast mass as compared to the tomosynthesis stack 202. For example, the 3D object grid 120 may use simulation techniques to infer a shape of the 3D object, even though an

image slice may not have necessarily been reconstructed at every cross-sectional depth covering the respective 3D object.

The 3D object grid 120 may comprise one or more objects, as shown in the illustrated embodiment. It should be 5 appreciated that these objects may be predefined objects that the system has been trained to identify. However, even in healthy breast tissue that does not necessarily comprise any abnormal objects or structures, the target object recognition/ enhancement modules may identify a breast background 10 object. For example, all breast linear tissue and density tissue structures can be displayed as the breast background object. In other embodiments, "healthy" objects such as spherical shapes, oval shapes, etc., may simply be identified through one or more target object recognition/enhancement 15 modules 210. These identified 3D objects may then be displayed on the 2D synthesized image 206; of course, out of all identified 2D objects, more clinically-significant objects may be prioritized and/or enhanced when displaying the respective object on the 2D synthesized image, as will be 20 discussed in further detail below.

In one or more embodiments, the 2D synthesizer 104 utilizes both the tomosynthesis image stack 202 along with the created 3D object grid 120 in order to merge the relevant features into one or more 2D synthesized images 206. As 25 shown in the 2D synthesized image, the 3D objects identified in the 3D object grid 120 are collapsed into a 2D format, but provide more detail when compared to individual image slices of the tomosynthesis image stack 202. Further, although several objects, as shown in the tomosynthesis 30 image stack 202 overlap in the z direction, identifying them as separate 3D objects allows the system to depict both objects clearly and efficiently. Simply utilizing legacy image recognizing techniques on the tomosynthesis image stack 202 may or may not necessarily provide such an accurate 35 synthesized 2D image 206. To explain, if there is overlap in the z direction of two structures, the two structures are essentially competing with each other for display on the 2D synthesized image 206. Thus, important aspects of both structures may be compromised. Or, only one of the two 40 structures may be highlighted at all in the 2D synthesized image 206. Or, in yet another scenario, the 2D synthesized image may depict both structures as one amorphous structure such that an important structure goes entirely undetectable for the end-user.

It will be appreciated that identifying 3D objects as separate objects with predefined types in the 3D object grid **120** allows the system to depict the structures more accurately on the 2D synthesized image **206**, and allows for various objects to be depicted simultaneously, even if there ⁵⁰ is an overlap of various objects in the coordinate space. Thus, utilizing the 3D object grid **120** has many advantages for producing a more accurate and visually-effective 2D synthesized image **206**.

In one or more embodiments, data from the tomosynthesis 55 stack **202** and the 3D object grid **120** are processed by one or more modules to produce the 2D synthesized image **206**. More particularly, an object combination module **210** may be configured to identify the various objects of the 3D object grid **120**, and determine a most optimal method to collapse 60 all the objects on a 2D plane/format. For example, the object combination module **210** may determine x and y coordinates for the plurality of objects and determine whether there are overlaps between multiple objects to be displayed on the 2D synthesized image **206**. In some embodiments, the object 65 combination module **210** may further be configured to determine which of the identified objects should be dis-

played on the 2D synthesized image **206**. This may be achieved through a training (or a "learning library" type) database **216** that stores an identity of various objects and associated weights of respective objects. The training database becomes more knowledgeable with the processing of each new patent breast image data, as the system derives 3D object models and (subsequently) detection mechanisms from this database, which will grow to include various samples of the same types of objects.

After the 3D objects are detected, then the next step is to utilize this same knowledge in synthesizing the 2D image. Since there may be many different types (or categories) of 3D objects, the weighting mechanism helps to combine the objects in the synthesis/data reduction process. For example, a dense spherical object may be weighed higher than a calcification (weighed 0.95 and 0.6 respectively in the illustrated embodiment), such that the dense spherical object may be enhanced to a greater degree as compared to a calcification. If the weight of an object is close to zero, the object combination module **210** may determine that the object need not be displayed at all, in some embodiments.

In one or more embodiments, an image details synthesis module **212** may be configured to determine what 3D objects or what areas within a 3D object should be emphasized in the 2D synthesized image **206**. For example, if there is an overlap between two objects, the image details synthesis module **212** may emphasize portions of both objects, and de-emphasize other portions of both objects such that both objects are clearly viewable on the 2D synthesized image. By manipulating aspects of both objects, the end-user may be able to identify both objects clearly. It should be appreciated that without this manipulation, both objects may simply be overlayed on top of each other, such that one object may simply be masked out and missed by the enduser.

For example, the 3D object grid **120** may include a calcification area and a spiculated lesion that overlap in the z direction. Without any specially designed image synthesis, a collapsed 2D format of the spiculated lesion and a collapsed 2D format of the calcification would be displayed on top of each other. Assuming the spiculated mass is larger, the spiculated mass may envelop the calcification entirely such that it is not visible to the end-user. Instead, the image details synthesis module **212** may emphasize the outline of the calcification area is visible. This image manipulation allows the end-user a clearer picture of significant objects on the 2D synthesized image **206**. FIG. **3**, described below, illustrates this system feature in further detail.

In some embodiments, the image details synthesis module 212 may comprise several algorithms and/or heuristics that are programmed with rules to determine what parts of an object to emphasize/de-emphasize based on the object database 216. For example, each object in the database 216 may correspond to metadata that defines most prominent and least-prominent features of the respective object. This metadata may be used by the various algorithms to determine which objects and/or which parts of objects to emphasize in the 2D synthesized images 206. By way of another example, a difference in weight between two overlapping objects may be calculated in order to determine whether both objects should be displayed. If the difference in weight is smaller than a predetermined threshold value, both objects may be displayed, but the assigned weight may be used to determine which of the two objects to emphasize over the other. However, if the difference in weight is larger than the

predetermined threshold value, only the object corresponding to the higher weight may be displayed at all. For example, if a dense spherical mass and calcification area are competing for display (difference of 0.35 in weight as per the illustrated embodiment) and the threshold value is set at 0.4, both objects may be displayed, but the spiculated mass (or parts of the spiculated mass) may be highlighted relative to the calcification area. However, if the spiculated mass and a benign semi-spherical mass are overlapping (difference of 0.65 in weight as per the illustrated embodiment), only the dense spherical mass may be displayed at all. Other rules may be defined to allow the system to modify the objects or portions thereof.

As noted above (and in FIG. 1), the 2D image synthesizer 104 further includes a data reduction engine 122 configured to receive the data input from the respective image details synthesis module 212 and object combination module 210, and to reduce any 3D objects identified therein into a low level 2D format that may be inserted into the 2D synthesized 20 image 206. In particular, and as described in further detail herein, the data reduction engine 122 accurately reduces the identified high-dimensional object of the 3D object grid 120 to a 2D format based on input received from the image details synthesis module 212, the database 216 and the 25 object combination module 210.

FIG. 3 depicts an example of how the 3D object grid may be utilized to generate the 2D synthesized images. In the illustrated embodiment, 3D object grid 304 includes at least two 3D objects: a spiculated mass 310, and a calcification area 312. When consulting a database, the object combination module may determine that both objects are important to display in the 2D synthesized image, the spiculated mass **310** being more significant than the calcification. However, $_{35}$ since both 3D objects 310 and 312 overlap in the z direction, the images may have to be manipulated such that both objects are still optimally displayed on the 2D synthesized image. In particular, the 2D synthesized image 306 displays a synthesized image that does not use any image manipu- 40 lation techniques described in this disclosure. As shown in 2D synthesized image 306, both 3D objects 310 and 312 are competing to be displayed, and neither object is displayed very clearly. More specifically, the calcification 312 is barely visible in the 2D synthesized image 306.

By contrast, referring to 2D synthesized image 308, the techniques described with respect to FIG. 2 are utilized in order to determine what parts of the respective 3D object should be emphasized and de-emphasized such that both objects are clearly discernible in the 2D synthesized image. 50 More particularly, although spiculated mass 310 is more significant than the calcification 312, the center portion of the spiculated mass 310 is slightly de-emphasized such that the calcification area is clearly visible. Similarly, it may be determined that the linear lines radiating from the center 55 portion should be emphasized such that the end-user understands a size or scope of the spiculated mass. In light of the modified image corresponding to the spiculated mass 310, the calcification 312 is now visible even though both objects overlap. Thus, as shown in FIG. 3, the 2D synthesized image 60 308 provides more details about both 3D objects 310 and 312 when compared to 2D synthesized image 306.

FIGS. 4A-4D depict exemplary embodiments of displaying various objects of the 3D object grid, while preserving clinically-significant information. In particular, the collaps- 65 ing of a 3D object into the 2D synthesized image may be achieved by the respective object combination module,

image synthesis module and data reduction module that work together to display as much clinically-significant information as possible.

FIG. 4A shows an example embodiment of an intra-object combination. Intra-object combination may refer to techniques used to represent a single object (that is captured on multiple Tr image slices 404) onto the 2D synthesized image. More particularly, an identified 3D object may appear in many consecutive Tr image slices as 408a, 408b and 408c. In theory these image patterns compete with each other for representation on the 2D synthesized image. Thus, an intra-object combination requires recognizing that all the images slices belong to the same 3D object, and only showing relevant information pertaining to the 3D object on the 2D synthesized image 406. Notably, as shown in FIG. 4A, the system may determine that all the image patterns 408a, 408b and 408c from the Tr stack 404 belong to the same 3D object, and may collapse them together such that they appear as one object 410 in the 2D synthesized image 406. In one or more embodiments, techniques such as averaging, MIP (maximum intensity projection), filtering, etc. may be used for intra-object combination. Intra-object combination techniques aim to preserve the structure of the 3D object without losing valuable information from any of the image slices, while minimizing competing information from multiple image slices that do not provide valuable information and/or visually confuse the end-user.

FIG. 4B illustrates an example embodiment of an object vs background combination. Object vs. background combination may be important for creating a natural-looking 2D synthesized image. The goal of this technique is to maintain useful information from objects together with meaningful background information representative of breast tissue. In the illustrated embodiment, the Tr stack 414 comprises two Tr image slices. The first image slice comprises a background image pattern 412. The second image slice comprises an object or a portion of an object 411. In collapsing information from the Tr stack 414 to the 2D synthesized image 416, some aspects of both image slices are emphasized while other aspects are de-emphasized. For example, in 2D synthesized image 416, the object 411 is preserved, and the background 412 is also rendered, but the middle portion of the background 412 is de-emphasized.

FIG. 4C illustrates an example embodiment of interobject combination without overlapping. In the illustrated embodiment, Tr stack 424 comprises two Tr image slices. One Tr image slice comprises object **422**, and the other Tr image slice comprises object 421. As shown in the illustrated embodiment, these objects do not overlap in the z direction. Thus, when collapsing both objects onto the 2D synthesized image 426, both objects 421 and 422 are represented clearly at their respective x-y locations.

FIG. 4D illustrates an example embodiment of interobject combination with overlap. This technique may be performed when two or more objects overlap to some degree. The two objects may be of the same type or of different types. In case of an overlap of objects, a hierarchical approach may be used to determine which object should be given precedence over the other. For example, if a higher weight is assigned to a first object, the first object may be emphasized in the 2D synthesized object, while the second object (or portions of the second object) may be de-emphasized. Or, if both objects are equally, or almost equally, important, both objects may be represented equally even if they are overlapping (and portions of both objects may be emphasized/de-emphasized such that both objects are clear in the synthesized 2D image).

In the illustrated embodiment, Tr image stack 434 comprises two Tr image slices. One Tr image slice comprises object 432, and the other Tr image slice comprises object **431**. As shown in the illustrated embodiment, these objects overlap in the z direction. Thus, when collapsing the objects 5 onto the 2D synthesized image 436, both objects 431 and 432 are represented, but are shown to overlap. Depending on weights assigned to both objects, one object may be highlighted while the other is de-emphasized. In the illustrated embodiment, both objects are represented somewhat 10 equally, even though it is clear that they represent two separate objects. In other embodiments (not shown), if object 431 is assigned a higher weight/priority, object 431 may be emphasized in the foreground, while object 432 may be relegated to the background. Similarly, other combination 15 techniques may be utilized to optimally represent clinicallysignificant information to the end-user.

FIG. 5 depicts an exemplary embodiment of collapsing information from a plurality of Tr images into a 2D synthesized image. In particular, a Tr image stack 504 may be used 20 to create a 3D object grid similar to the 3D grid shown in FIG. 2. The Tr stack 504 illustrates four distinct objects including two calcification areas 510 and 512, a spiculated mass 514, and a spherical mass 516. As discussed in detail above, identifying these four objects as separate and distinct 25 objects allows the system to accurately depict the objects as a whole on the 2D synthesized image 506. In the illustrated embodiment, the spiculated mass 514 is shown most prominently, while the calcifications and the spherical mass 516 are not as emphasized. This allows an end-user to easily 30 identify the most clinically significant part of the 2D synthesized image without being overwhelmed with objects that are less-significant.

FIG. 6 is a flow diagram 600 provided to illustrate exemplary steps that may be performed in an image merge 35 process carried out in accordance with one embodiment of the disclosed inventions. At step 602, an image data set is acquired. The image data set may be acquired by a tomosynthesis acquisition system, a combination tomosynthesis/ mammography system, or by retrieving pre-existing image 40 data from a storage device, whether locally or remotely located relative to an image display device. At step 604, a 3D object grid may be constructed by identifying various objects that are present in a 3D coordinate space representative of a patient's breast tissue. At step 606, the objects of 45 the 3D object grid are recognized, and a relative weight/ priority of each of the objects is determined. As discussed above, in some embodiments, all objects of the 3D object grid may be displayed, with some objects emphasized more than others. In other embodiments, only a subset of the 50 recognized objects may be displayed at all, while lesssignificant objects are omitted.

For example, it may be determined that one object is much more clinically significant as compared to another. Or, it may be determined that two overlapping objects are 55 equally significant. In this case, algorithms aiming to visually depict both objects optimally may be utilized, rather than highlighting one object over another. At step **608**, based on the relative weight/priority of the objects, the 3D objects may be reduced to a 2D format to create the 2D synthesized 60 image. This reduction process may highlight one object over another, in some embodiments. In other embodiment, the reduction process may highlight an outline of an object while de-emphasizing an interior of the object.

In yet another embodiment, the reduction process may 65 emphasize one or more features that are deemed to be significant, while de-emphasizing less significant aspects of

the same object. For example, in the case of a spiculated lesion, it may be important to display the blood supply lines emanating from the center of the spiculated mass, but the center of the spiculated mass, even if dense may be displayed with less emphasis. Any number of such enhancement techniques may be used in the data reduction process. At step **610**, the synthesized 2D image is displayed to the end-user.

Having described exemplary embodiments, it should be appreciated that the examples described above and depicted in the accompanying figures are only illustrative, and that other embodiments and examples also are encompassed within the scope of the appended claims. For example, while the flow diagrams provided in the accompanying figures are illustrative of exemplary steps; the overall image merge process may be achieved in a variety of manners using other data merge methods known in the art. The system block diagrams are similarly representative only, illustrating functional delineations that are not to be viewed as limiting requirements of the disclosed inventions. It will also be apparent to those skilled in the art that various changes and modifications may be made to the depicted and/or described embodiments (e.g., the dimensions of various parts), without departing from the scope of the disclosed inventions, which is to be defined only by the following claims and their equivalents. The specification and drawings are, accordingly, to be regarded in an illustrative rather than restrictive sense.

What is claimed is:

1. A method for processing breast tissue image data, comprising:

- processing an image data set including a plurality of image slices comprising image data of a patient's breast tissue to identify two or more clinically significant high-dimensional breast tissue objects in the breast tissue and to determine a clinically significant object type for each of the two or more clinically significant high-dimensional breast tissue objects;
- generating a high-dimensional object grid depicting each of the two or more high-dimensional breast tissue objects in the patient's breast tissue found across one or more respective image slices of the image data set;
- determining a confidence or probability of each of the two or more high-dimensional breast tissue objects depicted in the high-dimensional object grid;
- generating a synthesized image comprising a lower-dimensional format version of each of the two or more high-dimensional breast tissue objects depicted in the high-dimensional object grid based at least in part upon the confidence or probability of each of the two or more high-dimensional breast tissue objects, wherein the confidence or probability is determined based at least in part on a weight assigned to each of the two or more high-dimensional breast tissue objects, and wherein the weights assigned to the two or more high-dimensional breast tissue objects is based on the respective object type,
- where generating the synthesized image comprises:
 - determining whether the two or more high-dimensional breast tissue objects are likely to overlap in the displayed synthesized image; and
 - if it is determined that the two or more high-dimensional breast tissue objects are likely to overlap in the synthesized image, modifying at least one feature of at least one of the likely overlapping high-dimensional breast tissue objects such that one or more

most clinically significant features of at least one of the likely overlapping high-dimensional breast tissue objects is displayed.

2. The method of claim 1, further comprising generating the image data set including the plurality of image slices that 5 collectively depict the patient's breast tissue, wherein the high-dimensional object grid is generated based at least in part on the plurality of image slices.

3. The method of claim **1**, wherein generating the synthesized image comprising the lower-dimensional format 10 version of the two or more high-dimensional breast tissue objects includes modifying one or more aspects of at least one of the two or more high-dimensional breast tissue objects based at least in part on its respective determined confidence or probability. 15

4. The method of claim 1, wherein the lower-dimensional format version of the two or more high-dimensional breast tissue objects is based at least in part on an intra-object combination.

5. The method of claim **1**, wherein the lower-dimensional 20 format version of the two or more high-dimensional breast tissue objects is based at least in part on an inter-object combination.

6. The method of claim **1**, wherein the lower-dimensional format version of the two or more high-dimensional breast 25 tissue objects is based at least in part on combining a breast tissue object with a background.

7. The method of claim 1, further comprising displaying the synthesized image comprising the lower-dimensional format version of the two or more high-dimensional breast 30 tissue objects.

8. The method of claim 1, wherein the high-dimensional object grid comprises two or more high-dimensional breast tissue objects that depict normal and/or abnormal breast tissue structures. 35

9. The method of claim **8**, wherein the two or more high-dimensional breast tissue objects comprise a plurality of objects that collectively represent an entire breast parenchymal tissue structure.

10. The method of claim **8**, wherein each of the two or 40 more high-dimensional breast tissue objects is associated with a respective set of attributes, each attribute representing a characteristic of the breast tissue structure depicted by the respective high-dimensional breast tissue object.

11. The method of claim 10, wherein the set of attributes 45 collectively represent one or more of a location, a size, a shape, and a morphology of the respective breast tissue structure depicted by the high-dimensional breast tissue object.

12. The method of claim 8, wherein the two or more 50 high-dimensional breast tissue objects include two or more high-dimensional breast tissue objects corresponding to a first object type, and two or more high-dimensional breast tissue objects corresponding to a second object type.

13. The method of claim 12, wherein the first object type 55 corresponds to abnormal breast lesions including micro-calcifications and masses, and the second object type corresponds to normal breast structures including nipples, pectoral muscles, and breast parenchymal tissues.

14. The method of claim **13**, wherein a weight assigned to 60 objects of the first object type is greater than a weight assigned to objects of the second object type.

15. The method of claim **12**, further comprising using a pattern recognition method for each of the first and second object types to determine whether one or both object types ⁶⁵ are present in the image data set that depicts the patient's breast tissue.

16. The method of claim **15**, wherein the pattern recognition method utilizes one or more machine learning algorithms.

17. The method of claim **1**, further comprising, if it is determined that displaying both the two or more high-dimensional breast tissue objects that are likely to overlap in the synthesized image.

18. The method of claim 1, wherein modifying at least one feature of at least one of the overlapping high-dimensional breast tissue objects comprises modifying the object to emphasizing a first portion of the modified high-dimensional breast tissue object relative to a second portion of the same object.

19. A method for processing breast tissue image data, 15 comprising:

- processing an image data set including a plurality of image slices comprising image data of a patient's breast tissue to identify two or more clinically significant high-dimensional breast tissue objects in the breast tissue and to determine a clinically significant object type for each of the two or more clinically significant high-dimensional breast tissue objects;
- generating a high-dimensional object grid depicting each of the two or more high-dimensional breast tissue objects in the patient's breast tissue found across one or more respective image slices of the image data set;
- determining a confidence or probability of each of the two or more high-dimensional breast tissue objects depicted in the high-dimensional object grid;
- generating a synthesized image comprising a lower-dimensional format version of each of the two or more high-dimensional breast tissue objects depicted in the high-dimensional object grid based at least in part upon the confidence or probability of each of the two or more high-dimensional breast tissue objects, wherein the confidence or probability is determined based at least in part on a weight assigned to each of the two or more high-dimensional breast tissue objects, and wherein the weights assigned to the two or more high-dimensional breast tissue objects is based on the respective object type,

where generating the synthesized image comprises:

- determining whether two of the two or more highdimensional breast tissue objects are likely to overlap in the displayed synthesized image; and
- if it is determined that the two of the two or more high-dimensional breast tissue objects are likely to overlap in the synthesized image:
 - determining a difference in assigned weight of each of the two of the two or more high-dimensional breast tissue objects likely to overlap, and
 - if the determined difference is lower than a threshold value,
 - modifying one or more aspects of at least one of two of the two or more high-dimensional breast tissue objects, and
 - displaying both of the two of the two or more high-dimensional breast tissue objects likely to overlap in the synthesized image, wherein the modification pertains to emphasizing at least a portion of the high-dimensional breast tissue object assigned the higher weight relative to the high-dimensional object assigned the lower weight.

20. The method of claim **19**, wherein generating the synthesized image comprising the lower-dimensional format version of the respective two or more high-dimensional

breast tissue objects includes modifying one or more aspects of at least one of the two or more high-dimensional breast tissue objects to thereby emphasize high-dimensional breast tissue objects corresponding to the first object type over high-dimensional breast tissue objects corresponding to the 5 second object type.

21. The method of claim **19**, further comprising, if the determined difference is equal to or greater than the threshold value, displaying only one of the two of the two or more high-dimensional breast tissue objects likely to overlap in 10 the synthesized image, the displayed object being the one assigned the higher weight.

22. The method of claim **19**, wherein the first portion comprises an outline portion of the modified high-dimensional breast tissue object, and the second portion comprises 15 a middle portion of the same object.

23. The method of claim **19**, further comprising, if the determined difference is lower than a threshold value, modifying at least one of the two of the two or more high-dimensional breast tissue objects to emphasizing a first 20 portion of the modified high-dimensional breast tissue object relative to a second portion of the same object.

* * * * *